These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28387904)

  • 21. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
    Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
    Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.
    Badve S; Collins NR; Bhat-Nakshatri P; Turbin D; Leung S; Thorat M; Dunn SE; Geistlinger TR; Carroll JS; Brown M; Bose S; Teitell MA; Nakshatri H
    Am J Pathol; 2010 May; 176(5):2139-49. PubMed ID: 20228224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical profile and clinical-pathological variables in breast cancer.
    Cintra JR; Teixeira MT; Diniz RW; Gonçalves Junior H; Florentino TM; Freitas GF; Oliveira LR; Neves MT; Pereira T; Guerra MR
    Rev Assoc Med Bras (1992); 2012; 58(2):178-87. PubMed ID: 22569612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer.
    Nagelkerke A; van Kuijk SJ; Sweep FC; Nagtegaal ID; Hoogerbrugge N; Martens JW; Timmermans MA; van Laarhoven HW; Bussink J; Span PN
    Radiother Oncol; 2011 Oct; 101(1):39-45. PubMed ID: 21840613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.
    Tang P; Tse GM
    Arch Pathol Lab Med; 2016 Aug; 140(8):806-14. PubMed ID: 27472239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways.
    Chung S; Furihata M; Tamura K; Uemura M; Daigo Y; Nasu Y; Miki T; Shuin T; Fujioka T; Nakamura Y; Nakagawa H
    Oncogene; 2009 Aug; 28(32):2849-59. PubMed ID: 19483721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Expression and significance of phosphorylated Girdin in breast cancer].
    Xu Y; Fu L; Gu F; Ma YJ
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):205-9. PubMed ID: 22780975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extranuclear expression of hormone receptors in primary breast cancer.
    Kim R; Kaneko M; Arihiro K; Emi M; Tanabe K; Murakami S; Osaki A; Inai K
    Ann Oncol; 2006 Aug; 17(8):1213-20. PubMed ID: 16760268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
    Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
    Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Descriptive analysis of molecular subtypes in Tunisian breast cancer.
    Fourati A; Boussen H; El May MV; Goucha A; Dabbabi B; Gamoudi A; Sfar R; Rahal K; El May A; Ben Abdallah M
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):e69-74. PubMed ID: 23176549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.